Skip to main content
Premium Trial:

Request an Annual Quote

GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana

NEW YORK — GeninCode said on Monday that it has signed an agreement to commercialize its portfolio of polygenic cardiovascular disease products in the US with commercial services provider Eversana Life Sciences.

UK-based GeninCode offers a range of tests that combine genetic and clinical data to assess individuals for CVD risk including Cardio inCode for heart attack and other CVD-related conditions, Lipid inCode for familial hypercholesterolemia, and Sudd inCode for sudden cardiac death.

Under the terms of their deal, Milwaukee-based Eversana will launch GeninCode's products, beginning with Cardio inCode, using its complete commercialization offering, which includes clinical and commercial field teams, medical science liaisons, channel management, health economics, and outcomes research and compliance.

Financial and other terms were not disclosed.

"Eversana [provides] proven launch and commercialization expertise to support our market access and will help accelerate our speed to market," GeninCode CEO Matthew Walls said in a statement.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.